.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Accenture
Daiichi Sankyo
Boehringer Ingelheim
Citi
Covington
Farmers Insurance
Fish and Richardson
US Department of Justice
Novartis

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,551,620

« Back to Dashboard

Which drugs does patent 6,551,620 protect, and when does it expire?


Patent 6,551,620 protects APRISO and is included in one NDA. There has been one Paragraph IV challenge on Apriso.

This patent has ten patent family members in nine countries.

Summary for Patent: 6,551,620

Title: Pellet formulation for the treatment of the intestinal tract
Abstract:An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:09/906,494
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Valeant Pharms Intl
APRISO
mesalamine
CAPSULE, EXTENDED RELEASE;ORAL022301-001Oct 31, 2008RXYesYes► Subscribe► SubscribeYY FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,551,620

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,956,647Pellet formulation for the treatment of the intestinal tract► Subscribe
6,277,412 Pellet-type formulation intended for treating the intestinal tract► Subscribe
8,496,965Pellet formulation for the treatment of the intenstinal tract► Subscribe
8,940,328Pellet formulation for the treatment of the intestinal tract► Subscribe
8,337,886Pellet formulation for the treatment of the intestinal tract► Subscribe
7,547,451Pellet formulation for the treatment of the intestinal tract► Subscribe
8,911,778Pellet formulation for the treatment of the intestinal tract► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,551,620

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal977557► Subscribe
Japan4088413► Subscribe
Japan2001511441► Subscribe
Spain2196556► Subscribe
European Patent Office0977557► Subscribe
Denmark0977557► Subscribe
Germany59808642► Subscribe
Germany19732903► Subscribe
Canada2297832► Subscribe
Austria241964► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Chubb
Johnson and Johnson
Daiichi Sankyo
McKesson
Farmers Insurance
Argus Health
Covington
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot